Rifamail 300 Capsule contains Rifampicin 300mg, a first-line anti-tuberculosis agent widely used in the treatment of TB and other bacterial infections. It is an essential component of combination therapy for effective TB management.
Rifampicin works by inhibiting bacterial RNA polymerase, preventing protein synthesis and promoting rapid microbial clearance. Its efficacy in multi-drug TB regimens makes it indispensable in clinical practice.
Capsule formulation ensures accurate dosing, stable bioavailability, and ease of administration, supporting better patient adherence. Due to its critical role in TB treatment, Rifamail 300 Capsule maintains high demand in hospitals, clinics, and national TB programs.
Adding Rifamail 300 Capsule to your anti-tuberculosis and anti-infective portfolio enhances your range with a reliable, high-rotation product. Its prescriber trust, institutional adoption, and export potential make it ideal for PCD pharma companies, distributors, and third-party manufacturing partners.
Common side effects may include nausea, vomiting, abdominal discomfort, loss of appetite, or mild diarrhea. Rare but serious side effects include liver function abnormalities, allergic reactions, orange-red discoloration of body fluids, or thrombocytopenia. Patients should seek immediate medical attention if severe or persistent symptoms occur.
Rifamail 150 Capsule is indicated for the treatment of tuberculosis, leprosy, and other infections caused by susceptible Mycobacterium species, as part of combination therapy prescribed by a healthcare professional.
Rifamail 150 Capsule should be taken exactly as prescribed, preferably on an empty stomach, to ensure maximum absorption. Complete the full course of therapy to prevent resistance. Inform the doctor of any history of liver disease, kidney problems, or other concurrent medications.
Store Rifamail 150 Capsule in a cool, dry place away from direct sunlight. Keep out of reach of children and do not use beyond the expiry date printed on the packaging.